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Abstract
The purpose of this study was to design novel nanocapsules (NCs) with surface-chelated nickel
(Ni-NCs) as a vaccine delivery system for histidine (His)-tagged protein antigens. Ni-NCs were
characterized for binding His-tagged model proteins through high affinity non-covalent
interactions. The mean diameter and zeta potential of the optimized Ni-NCs was 214.9 nm and -
14.8 mV, respectively. The optimal binding ratio of His-tagged Green Fluorescent Protein (His-
GFP) and His-tagged HIV-1 Gag p41 (His-Gag p41) to the Ni-NCs was 1:221 and 1:480 w/w,
respectively. Treatment of DC2.4 cells with Ni-NCs did not result in significant loss in the cell
viability up to 24 h (<5%). We further evaluated the antibody response of the Ni-NCs using His-
Gag p41 as a model antigen. Formulations were administered subcutaneously to BALB/c mice at
day 0 (prime) and 14 (boost) followed by serum collection on day 28. Serum His-Gag p41 specific
antibody levels were found to be significantly higher at 1 and 0.5 μg doses of Gag p41-His-Ni-
NCs (His-Gag p41 equivalent) compared to His-Gag p41 (1 μg) adjuvanted with aluminum
hydroxide (AH). The serum IgG2a levels induced by Gag p41-His-Ni-NCs (1 μg) were
significantly higher than AH adjuvanted His-Gag p41. The Ni-NCs alone did not result in
elevation of systemic IL-12/p40 and CCL5/RANTES inflammatory cytokine levels upon
subcutaneous administration in BALB/c mice. In conclusion, the proposed Ni-NCs can bind His-
tagged proteins and have the potential to be used as antigen delivery system capable of generating
strong antigen specific antibodies at doses much lower than with aluminum based adjuvant and
causing no significant elevation of systemic proinflammatory IL-12/p40 and CCL5/RANTES
cytokines.
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1. Introduction
Subunit vaccines containing soluble protein antigens have been proposed as alternatives to
using whole organisms to generate immune responses because of reproducible immune
responses and better characterization [1]. However, many of these antigens are poorly
immunogenic if administered alone. Particulate antigen delivery systems like nanoparticles
(NPs), emulsions, microparticles and liposomes have been shown to enhance the recognition
of the antigens by the antigen presenting cells (APCs) and result in improved immune
response [2-5]. Formation of a depot at the site of injection has been proposed as a possible
mechanism of enhanced antigen recognition by particulate systems [6]. In addition to being
taken up efficiently by the APCs, NPs have the potential to release the entrapped antigen
over prolonged time. Moreover, surface modification allows incorporation of a variety of
antigens on the same particle and surface-coated ligands to target the APCs [7, 8].
The antigen can be either entrapped inside the matrix/core of the particle or coated on the
surface. The entrapment of protein in the core of a particle has problems associated with the
stability of the protein during the preparation of particles and poor entrapment [9]. The
surface coating of the antigen on the particle may be achieved by ionic interactions [10],
covalent conjugation [11] or non-covalent attachment [12]. We have previously reported
that increasing the affinity of the antigen to the surface of solid lipid NPs contributes to
enhanced immune responses as compared to the antigens associated on the surface via
simple adsorption or charge-charge interactions [10, 12].
In the present study, we investigated the formulation of novel nanocapsules (NCs) with
surface chelated nickel (Ni-NCs) in the outer shell and their potential to bind histidine (His)-
tagged proteins with high affinity through non-covalent attachment. The strong non covalent
interaction (KD ~ 10−6 – 10−14 M) between affinity ligands such as the His-tag on a protein
and transition metal ions like Ni and Cu has been investigated in detail and has been
successfully applied to protein purification [13-15]. This interaction is highly dependent on
individual protein, the site and length of His-tag and pH [14, 16]. Liposomes and iron oxide
NPs with surface chelated Ni have been previously proposed for the delivery and
purification of His-tagged proteins [17, 18]. We formulated the Ni-NCs using 1,2-dioleoyl-
sn-glycero-3-[(N-(5-amino-1-carboxypentyl) iminodiacetic acid) succinyl] (nickel salt)
(DGS-NTA-Ni), a lipid with NTA end group that can chelate Ni. Platt and co-workers
concluded that the association of NTA-Ni and his-tagged proteins is in micromolar range
which may be considered weak for in-vivo conditions. However, later studies comparing
NTA to trivalent NTA ligands suggested that increasing the affinity of this interaction did
not lead to an increase in immune responses [18, 19]. Although this report showed that
covalently bound antigen elicits stronger responses, the effect of the nature of association on
immune response may be antigen-specific as was reported by Shahum and Therien [20].
Moreover, it has been previously known that covalent modification of antigens is prone to
causing changes in the antigenicity and loss of binding [21]. Non-covalent attachment while
enhancing the antigen association is expected to preserve the antigenicity by ensuring the
presentation of the unmodified antigen.
Aluminum salts remain the only FDA approved particulate adjuvants. They have been
shown to induce strong antibody responses but there is uncertainty in induction of cellular
immunity [22]. Additionally, the use of aluminum containing salts has been linked to
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hypersensitivity reactions and physical or chemical alterations of the adsorbed protein
antigen in some cases [23]. NPs have been investigated for their superior safety profile and
an ability to protect the entrapped antigen [24]. In addition, we have reported strong humoral
and cellular immune responses against several protein antigens like TAT, p24 and Nef
coated onto solid lipid NPs and that NP bound antigens have the potential to generate CD8+
T cell responses [25].
In the present studies, we investigated a new type of lipid-based NCs developed in our
laboratory for their potential to deliver His-tagged proteins. His-Gag p41 was used as a
model antigen. We also compared the immune responses from our previously reported [12]
nickel decorated solid lipid NPs (Ni-NPs) to the novel Ni-NCs.
2. Materials and Methods
2.1 Materials and Reagents
Polyoxyethylene (20) stearyl ether (Brij® 78), d-α-tocopheryl polyethylene glycol 1000
succinate (Vitamin E TPGS) and Miglyol® 812 (caprylic/capric triglycerides) were
purchased from Uniqema (Wilmington, DE), Eastman Chemicals (Kingsport, TN) and Sasol
(Witten, Germany), respectively. Sepharose® CL-4B and DGS-NTA-Ni were obtained from
GE Healthcare (Piscataway, NJ) and Avanti Polar Lipids (Alabaster, AL), respectively.
Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) standard for Nickel was
purchased from Sigma Aldrich (St. Louis, MO) and N-terminal His-tagged GFP (His-GFP)
was purchased from Millipore (Billerica, MA). Aluminum hydroxide gel (Cat. No. AL226)
and emulsifying wax (comprised of cetyl alcohol and polysorbate 60 in a molar ratio of
20:1) were purchased from Spectrum Chemicals (Gardena, CA). CpG oligonucleotide (5′-
tcc atg acg ttc ctg acg tt -3′) (20 mer) (CpG ODN) was purchased from InvivoGen (San
Diego, CA).
2.2 Preparation of Ni-NCs
To prepare Ni-NCs, Brij 78 (3.5 mg), Vitamin E TPGS (1.5 mg) and Miglyol 812 (2.5 mg)
were weighed in a glass vial. DGS-NTA-Ni (varying amounts of 10 mg/mL stock solution in
chloroform) and 0.2 mL ethanol were added and mixed. The solvents were later evaporated
under nitrogen. The vial was placed in a water bath at 65°C and deionized water (1 mL)
preheated to 65°C was added while stirring the contents for 30 min. The Ni-NCs form
spontaneously and are composed of liquid core (Miglyol 812) and solid shell (Brij 78 and
Vitamin E TPGS). The suspension was cooled to room temperature and separated from free
components using a Sepharose CL-4B column (1.5 × 15 cm). The purified Ni-NCs were
characterized for particle size using Beckman Coulter N5 Submicron Particle Size Analyzer
(Beckman Coulter, Brea, CA) and zeta potential using a Malvern Nano-Z (Malvern
Instruments, Southborough, MA). Formulations were prepared by adding 0.1 mg (NC01),
0.25 mg (NC02) or 0.5 mg (NC03) DGS-NTA-Ni. A formulation with no DGS-NTA-Ni
(NC00) was prepared and used as control. For comparison, Ni-NPs were prepared as
previously reported [12]. Briefly, emulsifying wax (2 mg) and Brij 78 (3.5 mg) were
weighed in a glass vial and heated to 65°C. DGS-NTA-Ni (0.106 mg; 10 mg/mL stock
solution in chloroform) was added to the mixture. Deionized water (1 mL) was added and
the contents were stirred at 65°C to form a clear oil-in-water microemulsion. Ni-NPs were
obtained by cooling the microemulsion to room temperature that causes the solidification of
the core and the shell components. The Ni-NPs were purified as described above.
2.3 Determination of Surface Nickel Content
ICP-MS was used to quantify the amount of Ni on the surface of the Ni-NCs available for
binding to His-tagged ligands using Varian 820 Mass Spectrometer (Palo Alto, CA). A
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standard curve for Ni was prepared using Ni standard solution (1000 mg/L) in the
concentration range of 9 – 200 ppb. The recovery of Ni from the Ni-NCs was quantified by
spiking the standards with Ni-NCs dissolved in 0.2 mL of ethanol. To quantify the amount
of Ni on the surface, the Ni-NCs were diluted with 2% nitric acid, filtered through a 0.2 μm
filter and analyzed by ICP-MS. Ni concentrations were calculated from the previously
developed standard curve. Formulation NC02 was selected for further studies based on
lower polydispersity and higher DGA-NTA-Ni incorporation (wt %) compared to other
formulations (Table 1).
2.4 His-GFP Biding to Ni-NCs
To investigate the extent of accessible Ni on the surface, formulation NC02 was mixed with
His-GFP in several Ni to His-GFP molar ratios (1:0.1, 1:0.2, 1:0.4 and 1:0.8) and incubated
at 4°C overnight to allow for surface binding. Formulation NC00 was also incubated with
His-GFP (amount similar to that used in the ratio 1:0.2 above) to determine non-specific
association. The GFP-His-Ni-NC02 was separated from unbound His-GFP using a
Sepharose CL-4B column (1.5 × 15 cm) equilibrated with 10 mM PBS. Briefly, 0.2 mL
mixture was applied to the column and 1 mL fractions were collected. Subsequently, the
fluorescence associated with each fraction was measured (Ex 360/40, Em 528/20) on a
Synergy™ 2 Multi-Detection Microplate Reader (Biotek, Winooski, VT). The particle
intensity of each fraction was also measured and fractions containing GFP-His-Ni-NC02
were pooled and characterized for their particle size and zeta potential, respectively.
2.5 Microscopy
Formulation NC02 was visualized by transmission electron microscopy (TEM) to
understand the morphology of the particles. Briefly, 5 μL (approximately 1.6 × 106
particles) of diluted NC02 suspension was spread on a Pelco formvar coated 300 mesh
copper grid (01710-F, Ted Pella, Redding, CA). The suspension was allowed to air dry for 5
min. Any remaining liquid was wicked off. There was no additional staining. The grids were
then examined with a Zeiss EM 900 Transmission Electron Microscope using 50 kV
accelerating voltage. The images were acquired using photographic film which was
subsequently digitized.
2.6 Effect of GFP-His-Ni-NCs on the Viability of Dendritic Cells
The DC2.4 murine dendritic cell line was obtained from Dr. Kenneth L. Rock (Department
of Pathology, University of Massachusetts Medical School). The cells were cultured in
RPMI 1640 (ATCC) supplemented with 10% fetal bovine serum, 2 mM glutamine, 55 μM
beta-mercaptoethanol, non-essential amino acids, 10 mM HEPES buffer and 100 U/mL
penicillin and 100 μg/mL streptomycin (GIBCO). Trypan blue was used to determine
viability and cells were used for experiments when 70-80 % confluent.
The DC2.4 dendritic cells were incubated with different concentrations of NC02 for up to 48
h. The cells were trypsinized with 0.05 % Trypsin-EDTA (GIBCO), suspended in culture
medium, centrifuged at 200 g x 5 min and re-suspended in 10 mM PBS containing 1 mM
EDTA and 10 % fetal bovine serum. Propidium iodide (PI) was added to the cell suspension
as a viability marker at a final concentration of 1 μg/mL immediately before analysis by
flow cytometry. Flow cytometric analysis was performed using BD LSRII Flow Cytometer
(BD Biosciences, Mountain View, CA). Data analysis was performed using Flow Jo
7.6Software (Tree Star, Ashland, OR).
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2.7 His-Gag p41 Binding to Ni-NCs
Purified recombinant His-Gag p41 protein (HXB2 isolate) was generously provided by Dr.
Robert Seder (NIH-NIAID) and was used as model antigen. The protein was fluorescently
labeled using NHS-fluorescein. Briefly, 16 μg of NHS-fluorescein (186 μg/mL stock
solution in DMSO) was added to 325 μg of His-Gag p41 (1.2 mg/mL stock solution in 10
mM PBS). The mixture was incubated overnight at 4°C. Excess reactants were separated
from the protein using a desalting spin column. The degree of modification was calculated
using the molar extinction coefficient of fluorescein (ε = 68,000 M−1 cm−1, λmax = 493 nm).
The fluorescein-His-Gag p41 was incubated with NC02 in different weight ratios (His-Gag
p41:NC02) as described previously for His-GFP to estimate the binding of fluorescein-His-
Gag p41 to NC02.
2.8 Mouse Immunization Study
Eight to 10-weeks old female BALB/c mice (n = 5–7/group) from Charles River
Laboratories were used for immunization studies. The experimental design is shown in
Table 3. Formulations (100 μL) were administered subcutaneously in the nape of the neck
on day 0 and 14. Gag p41-His-Ni-NC02 (His-Gag p41:Ni-NCs weight ratio of 1:480) was
used to prepare three different concentrations that were subsequently administered to mice
to give three different doses of His-Gag p41. Gag p41-His-Ni-NP (His-Gag p41:Ni-NP
weight ratio of 1:100) were administered for comparison. Immune responses were compared
to His-Gag p41 adjuvanted with AH. An aqueous suspension of AH (4.8 mg/mL) was
prepared in deionized water by ultrasonication and His-Gag p41 (10 μg/mL) was added prior
to the injections. Mice were bled by cardiac puncture on day 28 and sera were collected. All
sera were stored at −20°C until further analysis.
2.9 Determination of Antibody Levels
His-Gag p41 specific serum IgG, IgG1 and IgG2a antibody levels were determined by
ELISA. Briefly, 96-well plates were coated with 50 μL His-Gag p41 (5 μg/mL in PBS)
overnight at 4°C. The wells were washed with PBS/Tween 20 and blocked using 4 % BSA
prepared in PBS/Tween 20 for 1 h at 37°C. Subsequently, the wells were washed with PBS/
Tween 20 and 50 μL of mouse serum at predetermined dilution was added and plates were
incubated for 2 h at 37°C. The wells were washed with PBS/Tween 20 and Horseradish
Peroxidase (HRP) conjugated Anti-mouse IgG F(ab/)2 fragment from sheep (50 μL of
1:3000 dilution in 1 % BSA in PBS/Tween 20) was added and incubated for 1 h at 37°C.
The wells were washed with PBS/Tween 20 and TMB (3,3,5,5-tetramethylbenzidine)
substrate (100 μL) was added to each well and incubated for 30 min at RT. Color
development was stopped by addition of 2M sulfuric acid and the absorbance at 450 nm was
measured on Synergy™ 2 Multi-Detection Microplate Reader (Biotek, Vinooski, VT). For
the determination of IgG1 and IgG2a, the plates were blocked for 1 h at 37°C as described
above followed by incubation with mouse serum for 1 h at RT. The plates were incubated
with biotinylated rat anti-mouse IgG1 or IgG2a for 1 h at RT followed by incubation with
streptavidin HRP for 30 min at RT. The plates were developed as described for IgG.
2.10 Systemic Cytokine Induction Studies
To investigate the induction of inflammatory cytokines upon s.c. administration of Ni-NCs,
8–10 weeks old female BALB/c mice (n = 3/time point) were used. Briefly, 0.48 mg of
NC02 or 10 μg CpG ODN (0.1 mg/mL in PBS) were administered to mice. Blood was
collected by cardiac puncture at 3, 6, 12, 24 and 48 h after administration. Sera were
collected and stored at −20°C. The serum concentration of IL-12/p40 and RANTES/CCL5
were determined by BD™ cytometric bead array (CBA) flex assay following manufacturer’s
protocol (BD Pharmingen, La Jolla, CA). Flow cytometric analysis was performed using
Wadhwa et al. Page 5













BD™ LSRII Flow Cytometer (BD Biosciences, Mountain View, CA). Data analysis was
performed using Flow Jo 7.6Software (Tree Star, Ashland, OR).
2.11 Statistical Analysis
Statistical analysis was performed using GraphPad Prism 4 Software (GraphPad Software,
San Diego, CA). Differences in antibody responses among treatment groups were analyzed
by one way ANOVA followed by Dunnet’s post-test to compare different treatments to the
naïve group. Effects on DC2.4 cell viability and cytokine induction results were analyzed by
regular two-way ANOVA followed by Bonferroni post-test to compare differences within
groups. Differences were considered significant at p<0.05.
3. Results
3.1 Preparation and Characterization of Ni-NCs
Our laboratory has recently reported the formulation of stable spontaneously forming NCs
containing a liquid oil core and surfactant-based shell prepared using biocompatible and
biodegradable components [26, 27]. The liquid core consists of Miglyol 812, which is a
mixture of caprylic and capric acid triglycerides, while the shell is composed of two
nonionic surfactants, Brij 78 and Vitamin E TPGS respectively. We modified the
formulation to contain a small amount of surface accessible nickel by incorporating DGS-
NTA-Ni in the shell (Fig. 1a). DGS-NTA-Ni has two out of the six co-ordination sites
available to interact with the His residues on proteins. Formulations prepared during the
optimization of NCs with or without surface accessible nickel. The incorporation of DGS-
NTA-Ni was determined by measuring the amount of Ni by ICP-MS. Based on the
incorporation efficiency of DGS-NTA-Ni determined by ICP-MS analysis and desired
particle size range, formulation NC02 was selected for further studies. The optimized NCs
had mean particle size of 214 nm with very low polydispersity upon gel filtration and had
negative surface charge density as indicated by zeta potential measurements in 0.5 mM
phosphate buffer (Table 1). The negative charges can be due to the formation of small
amounts of metal oxides or accumulation of negative ions on the surface of the NCs. It is
interesting to note that the relationship between nickel incorporation and zeta potential is
non-linear for NCs described in the present study. This may be explained by partial
solubility of DGS-NTA-Ni in the core of NCs whereby the NTA-Ni entrapped in the core of
NCs does not contribute to the zeta potential of the NPs. We also formulated previously
reported Ni-NPs to investigate the effect of particle morphology on antigen delivery [12].
The Ni-NPs have a solid matrix core composed of emulsifying wax coated with a single
surfactant.
3.2 Protein Binding
His-GFP was used as a model protein to study the interaction of His-tag with surface Ni and
investigate the binding efficiency of the Ni-NCs. His-GFP can be easily detected by
fluorescence making it easier to quantitatively determine the amount of protein bound to the
surface and qualitative assessment by microscopy [28]. The GFP-His-Ni-NC02 was
separated from unbound His-GFP using gel filtration (Sepharose CL-4B). The fluorescence
associated with the particles compared to the fluorescence of the unbound fractions was used
to derive the percent of His-GFP bound to the Ni-NCs (Fig. 2a). The elution of particles
from the gel was monitored using particle intensity measurements by light scattering. Based
on trials using different ratios of surface Ni to His-GFP, Ni-NCs (NC02-02) incubated at
molar ratio of 1:0.2 (Ni:His-GFP) resulted in the highest level of binding (35 %).
Interestingly, increasing the amount of GFP did not increase the association (Table 2). This
indicates that only a limited number of DGS-NTA-Ni are accessible on the surface of the
NCs and the binding is therefore, saturable. Theoretical calculations showed that the weight
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ratio His-GFP: Ni-NC in formulation NC02-02 was 1:221 and the ratio of molecules of Ni
(13,300) to molecules of His-GFP (885) was approximately 15. This is expected as the much
larger surface area of His-GFP may result in shielding of the surface Ni and the ability of
single His-tag residue to complex with multiple Ni atoms. The binding of protein on the
surface did not significantly affect the particle size and zeta potential of Ni-NCs (data not
shown). Formulation NC00 was used as controls to determine non-specific binding of His-
GFP which was found to be negligible (Fig. 2a). The results from this study provide an
evidence of surface binding of His-tagged proteins that was specific to Ni-NCs. The binding
experiments were also performed using fluorescein-His-Gag p41. The weight ratio of 1:480
(His-Gag p41: NC02) resulted in more than 65% of the protein associated with the NC02
(Fig. 2b).
3.3 Microscopy
To examine the morphology of the Ni-NCs, NC02 suspension was observed by TEM. As the
Ni-NCs have a soft structure and all the components have lower melting points, the protocol
involved air drying of the grids. The NCs appeared as hollow spheres that confirms the
presence of a fluid core (Fig. 1b). This is in contrast to similar TEM studies performed with
our previous solid lipid nanoparticles where the core is composed of waxy solid and the
particles appear as opaque spheres [29]. The size observed by TEM was smaller than that
measured by dynamic light scattering. The NCs of the present study have an internal fluid
structure comprised of an aqueous-bound shell. This may contribute to shrinkage and
collapse during drying and imaging.
3.4 Toxicity of NCs in Dendritic Cells
Dendritic cells are the most important APCs. Particulate delivery systems are suited for
rapid uptake by the dendritic cells due to their size.The cytotoxicity of the Ni-NCs (NC02)
to DCs following treatment with NCs for 12, 24 or 48 h was investigated by flow cytometry
(Fig. 3). At 12 and 24 h, none of the concentrations tested resulted in >5% increase in
cytotoxicity over untreated cells. However, at 48 h, the Ni-NC treatment resulted in
significant cytotoxicity to DCs. In our previous studies, we have reported significant
cytotoxicity in DCs treated with lower concentrations of Ni-NPs (11 μg/mL) [8]. In-vivo,
this difference may result in Ni-NCs being better tolerated compared to Ni-NPs making it
possible to dose higher concentrations of protein-bound NCs.
3.5 Immunization Study
Mice were immunized with three different doses of His-Gag p41/Ni-NCs (fixed weight ratio
of 1:480) to investigate a His-Gag p41 dose response in the antibody generation.
Comparisons were made with His-Gag p41 adjuvanted with AH. At 1:1000 sera dilution, the
Ni-NCs resulted in stronger antibody response compared to AH at both the 1 μg and 0.5 μg
His-Gag p41 doses (Fig. 4a). When compared at the same sera dilution, the OD (450 nm)
values for NCs at the 1 μg dose were >4-fold higher than those for Ni-NPs. As discussed
above, it is possible that the toxicity to APCs may have contributed to weaker antibody
response observed with the Ni-NPs.
The serum isotype levels, IgG1 and IgG2a, were determined by ELISA to investigate the
type of immune response at 1:500 serum dilution for all the formulations. While production
of IgG2a isotype has been associated with Th1 response, IgG1 isotype has been associated
with Th2 type response. The ratios of IgG2a/IgG1 were used to indicate the Th1 or Th2 bias
of the generated immune response [30, 31]. A balanced Th1 and Th2 response is desired
following vaccination as excess of either will result in adverse effects. Aluminum containing
salts have been reported to generate a Th2 biased response [32, 33]. This is expected to
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result in a lower IgG2a/IgG1 ratio. In our observations, the ratio IgG2a/IgG1 was 0.14 for
AH and 0.55 for Ni-NCs at highest dose of His-Gag p41 (1 μg) respectively (Fig. 4b).
3.6 Systemic Cytokine Induction Studies
To investigate the immunostimulating activity of Ni-NCs, we determined the induction of
pro-inflammatory cytokines by Ni-NCs (formulation NC02). CpG ODN was administered as
strong inducer of pro-inflammatory cytokines. We determined serum concentrations of
IL-12/p40 and CCL5/RANTES upon s.c. injection of Ni-NCs in comparison to CpG ODN
and untreated animals. The results demonstrate that Ni-NCs did not result in significant
elevation in the level of any of the cytokines measured over control while CpG was a strong
inducer of both the cytokines (Fig. 5). This indicates that the Ni-NCs are potentially a safe
delivery vehicle and may result in fewer adverse events upon administration. However, this
also indicates that additional (safe) adjuvant(s) may be needed in certain cases to potentiate
the immune response by Ni-NCs.
4. Discussion
This study aimed at developing NCs with chelated Ni on the surface thus providing binding
sites for His-tagged antigens. The Ni-NCs of the present study are composed of completely
metabolizable or biocompatible components and have the ability to carry multiple antigens
as well as an adjuvant. Therefore, using them as a vehicle for the delivery of vaccines is a
promising approach.
Delivery of antigen by particulate systems requires their association or entrapment within
the particle. The effect of the type of association on the resulting immune response has been
a matter of debate over the past two decades and several contradicting reports have been
published [19, 20]. In our previous studies, we observed that increasing the association of
the antigen to the surface of the NPs increased the associated antibody responses [12].
Continuing on the previously obtained results, we investigated non-covalent attachment of
the antigen to the NPs exploiting the Ni-His interaction. NTA has been used as a popular
ligand for Ni in delivery systems [34]. The effect of spacer group and the valency show that
while the length of the spacer may have some effect on the accessibility, the valency does
not affect the antibody responses [19, 35]. The Ni-NCs exhibited specific binding ability for
His-tagged model protein although the extent of binding can be increased by improving the
binding affinity of surface nickel. This may be done by modifying the length and
amphiphilicity of the spacer group to reduce steric effects on the surface of the NPs although
some steric hindrance is desired to reduce the exchange of the bound protein with other His-
tagged proteins or serum proteins.
The overall safety and absence of hypersensitivity are desirable features of a vaccine
formulation. The presence of Ni in the formulations of the present study may be of concern
in view of studies implicating adverse events like immunosuppression [36] and
carcinogenicity [37] upon parenteral administration of Ni compounds and Ni containing
products. However, the highest dose of the Ni administered in the form of Ni-NCs in the
present study was 70 ng. This is approximately 10,000-fold less than the doses shown to
cause immunosuppression or carcinogenicity and is expected to be well tolerated.
Additionally, the average dietary intake of Ni in humans is estimated to be 69-162 μg/day
(Safe Use of Nickel, 2008). Chikh et al. reported no toxicity upon acute s.c. dosing (three
weekly injections) of liposomes containing 5% and 10% DGS-NTA-Ni in mice for 30 days
[38]. To further address this, we examined the serum levels of IL-12/p40 and CCL5/
RANTES in mice treated with Ni-NCs. We observed no significant induction of systemic
pro-inflammatory cytokines by s.c. administered Ni-NCs. Nevertheless, further investigation
of immune response to DGS-NTA-Ni may be needed and antigen delivery systems using
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components containing Ni must be evaluated for their safety in individuals where adverse
events may be expected.
The type of desired immune response, humoral or cellular, is affected by many factors
including the nature of the pathogen or the antigen, its mode of entry, types of cells infected
and cellular localization, the purpose of immune induction (therapeutic or prophylactic) and
host features among others. In most cases, both humoral and cellular responses are desired.
Interestingly, particulate antigen delivery systems have shown enhanced cross-MHCI
presentation due to their endocytic uptake and thus may lead to both humoral and long-
lasting cellular responses making them ideal adjuvants [39, 40]. Interestingly, we have
previously shown a strong cytotoxic T-cell and antibody response with the Ni-NPs similar to
those used for comparison in the present study [25].
We are currently evaluating T-cell responses to further investigate the type of immune
responses. To further improve the immune response with the Ni-NCs, we are also
investigating the addition of an immunostimulant adjuvant in the Ni-NCs by either surface
conjugation or incorporation in the core.
5. Conclusions
We have successfully formulated novel NCs with surface accessible Ni and investigated
binding of two His-tagged proteins, GFP and Gag p41, respectively, to the surface of Ni-
NCs. The Ni-NCs are non-toxic up to 24 h at high concentrations. Enhanced antibody
responses were observed compared to AH at much lower doses of the antigen. Treatment
with Ni-NCs resulted in a higher IgG2a/IgG1 ratio compared to AH. The Ni-NCs did not
stimulate the production of systemic proinflammatory cytokines, IL-12/p40 and CCL5/
RANTES after s.c. injection. Future efforts involve conjugation of different adjuvants on the
surface of the Ni-NCs in addition to the surface decoration with a protein antigen to create a
system that has both immune-potentiation and efficient antigen delivery characteristics. We
also plan to investigate the retention and migration of Ni-NCs from the site of
administration.
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Fig. 1. Nanocapsules (NCs) with surface accessible nickel (Ni-NCs)
a) Ni-NCs having a core and shell morphology were formulated with DGS-NTA-Ni to
provide surface accessible nickel for binding to His-tagged proteins. Four out of the six co-
ordination sites of Ni in DGS-NTA-Ni are occupied while the two remaining sites are
available for His-tagged ligand binding; b) TEM image of Ni-NCs. The distance between
the arrowheads within the blackbox corresponds to 150 nm.
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Fig. 2. Binding of His-tagged proteins to Ni-NCs
a) Ni-NCs formulated with (formulation NC02) or without (formulation NC00) surface Ni
were compared to determine specific and non-specific binding of His-GFP as a model
protein, and to determine the binding efficiency of the Ni-NCs. The Ni-NCs were separated
from unbound His-GFP by elution from a Sepharose CL-4B column (1.5 × 15 cm) using 10
mM PBS as the elution medium. The elution of Ni-NCs was monitored by measuring the
particle intensity (PI) while the fluorescence intensity (FI) was measured to determine His-
GFP associated with each fraction; b) Binding of fluorescein-His-Gag p41 to the surface of
Ni-NCs (formulation NC02) was determined similarly.
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Fig. 3. Interaction of Ni-NCs with DC2.4 dendritic cells
DC2.4 dendritic cells (1 × 105) were treated with formulation NC02 (0.04, 0.4, 4 and 40 μg/
ml) following which they were stained with propidium iodide and analyzed by flow
cytometry. Data represents mean ± SEM (n = 3). *p<0.01.
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Fig. 4. Antibody responses in BALB/c mice
a). Female BALB/c mice were immunized on days 0 and 14 with 100 μL of Gag p41-His-
Ni-NPs, Gag p41-His-Ni-NC02 or His-Gag p41 adjuvanted with Aluminum Hydroxide
(AH); b) Serum samples were also analyzed for IgG1 and IgG2a levels. His-Gag p41-
equivalent dose is indicated in parentheses on X-axis. Serum was analyzed on day 28 by
ELISA. Data represents mean ± SEM (n = 6–7). # p<0.05, * p<0.01, **p<0.001 compared to
naïve (untreated) group.
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Fig. 5. Serum cytokine analysis
Serum levels of a) IL-12/p40 and b) CCL5/RANTES were measured at predetermined time
points following s.c. administration of formulation NC02 (0.48 mg) in female BALB/c mice.
CpG ODN (10 μg) was administered as positive control. Analysis was performed by
cytometric bead array flex assay. Data represents mean ± SEM (n = 3), ** p<0.001.
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Table 1
Physicochemical characterization of the representative NC formulations with or without the incorporation of
surface chelated nickel.
Formulation/
Parameters NC00 NC01 NC02 NC03
Particle Size (nm)
(Mean ± SD; n=3) 197.2 ± 59.3 199.7 ± 67.4 214.9 ± 57.1 270.2 ± 145.2
Zeta Potential (mV) −7.8 −16.2 −14.8 −35.9
Nickel Content
(ng/mg NPs; Mean ± SD; n=2) ND 29.5 ± 2.8 145.6 ± 19.5 228.4 ± 38.5
ND = Not detected.
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Table 2










Ni-NCs were incubated with His-GFP at different molar ratios of Ni:His-GFP. The GFP-His-Ni-NCs were purified and the percentage of
fluorescence associated with NCs was calculated.
*
Formulation NC02 was incubated with His-GFP to estimate non-specific binding in the absence of surface nickel. The amount of GFP incubated
with NC00 was equivalent to that used in NC02 (Ni:His-GFP of 1:0.2) trial.
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Table 3
Mouse immunization study design.
Group/Dose NCs (mg) His-Gag p41
equivalent (μg)
Naive 0 0
Gag p41-His-Ni-NCs (NC02) 0.48 1
Gag p41-His-Ni-NCs (NC02) 0.24 0.5
Gag p41-His-Ni-NCs (NC02) 0.048 0.1
AH + His-Gag p41 0.48 1
Gag p41-His-Ni-NPs 0.1 1
Female BALB/c mice were s.c. administered treatments on day 0 (prime) and 14 (boost). Sera were collected on day 28 and analyzed by ELISA.
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